Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Toussirot

Showing results (1-10 of 146) with videos related to

Pageof 15
Sort By:
Inflammation & Allergy Drug Targets|January 28, 2012
The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseasesEric Toussirot
Presse Medicale (Paris, France : 1983)|April 24, 2012
[Adipokines: some players of inflammation in inflammatory rheumatic diseases and systemic autoimmune diseases?]Eric Toussirot
Drugs & Aging|June 30, 2010
Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapiesEric Toussirot
Metabolites|March 19, 2020
The Interrelations between Biological and Targeted Synthetic Agents Used in Inflammatory Joint Diseases, and Obesity or Body CompositionEric Toussirot
Expert Opinion on Pharmacotherapy|June 15, 2023
Advances in pharmacotherapies for axial spondyloarthritisEric Toussirot
Inflammation & Allergy Drug Targets|March 17, 2010
Predictive factors for disability as evaluated by the health assessment questionnaire in rheumatoid arthritis: a literature reviewEric Toussirot
Expert Opinion on Pharmacotherapy|January 19, 2017
New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agentsEric Toussirot
Joint Bone Spine|December 22, 2009
Correspondence to the article by Park Min-Chan "Pro-inflammatory effect of leptin on peripheral blood mononuclear cells of patients with ankylosing spondylitis" Joint Bone Spine 2009;76:170-75Eric Toussirot
Expert Opinion on Biological Therapy|December 1, 2017
Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritisEric Toussirot
Frontiers in Medicine|December 3, 2021
The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current InsightsEric Toussirot
Pageof 15

Showing results (1-10 of 146) with videos related to

Sort By:
Pageof 15
Inflammation & Allergy Drug Targets|January 28, 2012
The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseasesEric Toussirot
Presse Medicale (Paris, France : 1983)|April 24, 2012
[Adipokines: some players of inflammation in inflammatory rheumatic diseases and systemic autoimmune diseases?]Eric Toussirot
Drugs & Aging|June 30, 2010
Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapiesEric Toussirot
Metabolites|March 19, 2020
The Interrelations between Biological and Targeted Synthetic Agents Used in Inflammatory Joint Diseases, and Obesity or Body CompositionEric Toussirot
Expert Opinion on Pharmacotherapy|June 15, 2023
Advances in pharmacotherapies for axial spondyloarthritisEric Toussirot
Inflammation & Allergy Drug Targets|March 17, 2010
Predictive factors for disability as evaluated by the health assessment questionnaire in rheumatoid arthritis: a literature reviewEric Toussirot
Expert Opinion on Pharmacotherapy|January 19, 2017
New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agentsEric Toussirot
Joint Bone Spine|December 22, 2009
Correspondence to the article by Park Min-Chan "Pro-inflammatory effect of leptin on peripheral blood mononuclear cells of patients with ankylosing spondylitis" Joint Bone Spine 2009;76:170-75Eric Toussirot
Expert Opinion on Biological Therapy|December 1, 2017
Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritisEric Toussirot
Frontiers in Medicine|December 3, 2021
The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current InsightsEric Toussirot
Pageof 15